Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine

Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine

© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 25(2013), 41 vom: 06. Nov., Seite 5928-36
1. Verfasser: Xu, Ligeng (VerfasserIn)
Weitere Verfasser: Liu, Ye, Chen, Zhiyun, Li, Wei, Liu, Ying, Wang, Liming, Ma, Liying, Shao, Yiming, Zhao, Yuliang, Chen, Chunying
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't HIV-1 fullerenol nano-adjuvant vaccine virus-like particle AIDS Vaccines Adjuvants, Immunologic Fullerenes mehr... Vaccines, DNA Vaccines, Virus-Like Particle 182024-42-6
LEADER 01000naa a22002652 4500
001 NLM230201547
003 DE-627
005 20231224083842.0
007 cr uuu---uuuuu
008 231224s2013 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.201300583  |2 doi 
028 5 2 |a pubmed24n0767.xml 
035 |a (DE-627)NLM230201547 
035 |a (NLM)23963730 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Xu, Ligeng  |e verfasserin  |4 aut 
245 1 0 |a Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 06.10.2014 
500 |a Date Revised 11.03.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
520 |a Fullerenol, which self-assembles into virus-sized nanoparticles, is designed as a dual-functional nanoadjuvant to generate comparable immune responses to the HIV DNA vaccine. It shows promising adjuvant activity via various immunization routes, decreasing the antigen dosage and immunization frequency while maintaining immunity levels and inducing TEM -biased immunity to combat the infection at early stage. The underlying mechanisms by which fullerenol-based formulation induces above-mentioned polyvalent immune responses are involved in activating multiple TLRs signaling pathways 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a HIV-1 
650 4 |a fullerenol 
650 4 |a nano-adjuvant 
650 4 |a vaccine 
650 4 |a virus-like particle 
650 7 |a AIDS Vaccines  |2 NLM 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Fullerenes  |2 NLM 
650 7 |a Vaccines, DNA  |2 NLM 
650 7 |a Vaccines, Virus-Like Particle  |2 NLM 
650 7 |a fullerenol  |2 NLM 
650 7 |a 182024-42-6  |2 NLM 
700 1 |a Liu, Ye  |e verfasserin  |4 aut 
700 1 |a Chen, Zhiyun  |e verfasserin  |4 aut 
700 1 |a Li, Wei  |e verfasserin  |4 aut 
700 1 |a Liu, Ying  |e verfasserin  |4 aut 
700 1 |a Wang, Liming  |e verfasserin  |4 aut 
700 1 |a Ma, Liying  |e verfasserin  |4 aut 
700 1 |a Shao, Yiming  |e verfasserin  |4 aut 
700 1 |a Zhao, Yuliang  |e verfasserin  |4 aut 
700 1 |a Chen, Chunying  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 25(2013), 41 vom: 06. Nov., Seite 5928-36  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:25  |g year:2013  |g number:41  |g day:06  |g month:11  |g pages:5928-36 
856 4 0 |u http://dx.doi.org/10.1002/adma.201300583  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 25  |j 2013  |e 41  |b 06  |c 11  |h 5928-36